12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
One practice that has plagued the insurance industry in recent years has been contractors soliciting...
Read More >
Join Sherman & Howard for our annual Construction Law Seminar, featuring presentations on the latest...
Read More >
For decades, federal wage and hour regulations have required that non-discretionary bonuses paid to ...
Read More >
On August 5, 2019, the Department of Labor (“DOL”) published proposed revisions to the Wage and Ho...
Read More >
On August 12, the National Labor Relations Board (the Board) published a Notice of Proposed Rulemaki...
Read More >
Dear YouDig?, I admit it. As an engineer I like to tinker. A few months in to a factory project our...
Read More >